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Abstract 
β-adrenergic  signaling  is  involved  in  the
development of cardiac hypertrophy (CH), justi-
fying the use of β-blockers as a therapy to min-
imize and postpone the consequences of this
disease.  Evidence  suggests  that  adenylate
cyclase, a downstream effector of the β-adren-
ergic pathway, might be a therapeutic target.
We examined the effects of the anti-epileptic
drug  carbamazepine  (CBZ),  an  inhibitor  of
adenylate cyclase. In a murine cardiac hypertro-
phy model, carbamazepine significantly attenu-
ates  isoproteronol  (ISO)-induced  cardiac
hypertrophy. Carbamazepine also has an effect
in transverse aortic banding induced cardiac
hypertrophy  (TAB)  (P=0.07).  When  carba-
mazepine was given in combination with the
antibiotic  doxycycline  (DOX),  which  inhibits
matrix metalloproteinases (MMPs), therapeu-
tic outcome measured by heart weight-to-body
weight and heart weight-to-tibia length ratios
was improved compared to either drug alone.
Additionally, the combination therapy resulted
in an increase in the survival rate over a 56-day
period compared to that of untreated mice with
cardiac hypertrophy or either drug used alone.
Moreover, in support of a role for carbamaze  -
pine  as  a  β-adrenergic  antagonist  via  cAMP
inhibition, a lower heart rate and a lower level
of  the  activated  phosphorylated  form  of  the
cAMP Response Element-Binding (CREB) were
observed in heart extracts from mice treated
with carbamazepine. Gene expression analysis
identified 19 genes whose expression is signif-
icantly altered in treated animals and might be
responsible for the added benefit provided by
the combination therapy. These results suggest
that  carbamazepine  acts  as  a  β-adrenergic
antagonist.  Carbamazepine  and  doxycycline
are  approved  by  the  US  Food  and  Drug
Administration (FDA) as drugs that might com-
plement medications for cardiac hypertrophy or
serve as an alternative therapy to traditional β-
blockers.  Furthermore,  these  agents  repro-
ducibly  impact  the  expression  of  genes  that
may serve as additional therapeutic targets in
the management of cardiac hypertrophy.
Introduction
Cardiac hypertrophy (CH) frequently devel-
ops  in  response  to  biomechanical  stress  or
increased cardiac afterload, such as in the set-
ting of systolic hypertension or aortic stenosis.
Hypertrophic hearts often develop contractile
dysfunction  and  decreased  cardiac  perform-
ance, with an increased risk for heart failure,
ischemic heart disease, and sudden death.
1,2
Cardiac  hypertrophy  remains  a  chronic  and
progressive process even though a number of
generally-acceptable medication therapies are
available,  such  as  angiotensin  converting
enzyme  (ACE)  inhibitors  and  beta  blockers.
More  effective  therapies  are  still  needed  to
prevent heart deterioration in individuals with
hypertrophy  and  to  reduce  unwanted  side
effects associated with current medications.    
The process of cardiac hypertrophy develop-
ment is complex, and there are multiple molecu-
lar signaling pathways contributing to the hyper-
trophic  response  triggered  by  mechanical
stress.
3-5Perhaps the best characterized is the β-
adrenergic  pathway,  which  is  a  major  hyper-
trophic stimulus mediated via a G protein-cou-
pled  receptor  that  activates  adenylate  cyclase
and  subsequently  cAMP  production.  Isopro  -
terenol  (ISO),  a  β-adrenergic  agonist  that
induces cardiac hypertrophy in mice, has been
previously shown to increase cAMP production
in cultured myocytes, comparable to forskolin-
induced cAMP levels.
6Similarly, disruption of the
gene  encoding  adenylate  cyclase  has  been
shown  to  prevent  ISO-  or  pressure  overload-
induced cardiac hypertrophy.
7Moreover, β-block-
ers are well established as therapies that count-
er the consequences of hypertension and hyper-
trophy by preventing stimulation of this pathway
and subsequently improving the survival rates of
patients suffering from hypertrophy or heart fail-
ure.
8-10 To discover potential new therapies for
cardiac  hypertrophy,  we  used  IRIDESCENT,  a
computational program that can identify previ-
ously unknown relationships between medical
objects in PubMed such as small molecules, phe-
notypes, and genes.
11 This novel method of data
mining has been shown to be a useful tool for
identifying potential drug candidates and previ-
ously predicted the known relationship between
chlorpromazine and cardiac hypertrophy.
12 IRI-
DESCENT  predicted  several  other  therapeutic
candidates  which  were  further  screened  by
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examining their published modes of action and
potential  for  targeting  pathways  known  to  be
important for cardiac hypertrophy. One candidate
was  the  antibiotic  doxycycline  (DOX)  which
inhibits MMPs. We have previously shown that
doxycycline attenuates the hypertrophic pheno-
type  in  mice  challenged  with  isoproterenol  or
transverse aortic banding and that doxycycline
was  able  to  reduce  potential  signaling  events
associated  with  cardiac  hypertrophy,  including
MMP2/9 activation, upregulation of EDG1 recep-
tor and activation of ERK, p-38, and the transcrip-
tion factor ATF-2.
13 Another candidate selected
from IRIDESCENT predictions is the anti-epilep-
tic  carbamazepine.  Carbamazepine  has  been
shown to decrease both basal and forskolin-stim-
ulated cAMP production by inhibiting adenylate
cyclase and its downstream effects.
14,15,16 In this
study,  we  tested  the  efficacy  of  both  carba-
mazepine and doxycycline in a mouse model of
cardiac  hypertrophy  and  found  that  carba-
mazepine significantly attenuated hypertrophy.
When  carbamazepine  and  doxycycline  were
administered in combination, the hypertrophic
phenotype  was  further  decreased  and  survival
increased.  Our  results  suggest  that  carba-
mazepine mediates these beneficial effects by
interfering with β-adrenergic signaling.
To further define the specific molecular sig-
naling events that might be altered by doxycy-
cline and carbamazepine treatment, we also
performed hybridization microarray analysis to
measure differential gene expression and to
identify other potential molecular targets for
the management of cardiac hypertrophy.
Materials and Methods 
Isoproterenol induced cardiac
hypertrophy
All animal studies were conducted in accor-
dance with the standards set forth in published
guidelines
17 and  were  approved  by  our
Institutional Animal Care and Use Committee.
Eight-week-old C57BL/6J male mice (Jackson
Laboratory) were given isoproterenol (Sigma
Aldrich) at 40 mg.kg
–1.d
–1 administered S.Q. via
micro-osmotic pump insertion (ALZET 1007D).
Briefly, animals were anesthetized with 1.5%
isoflurane and 98.5% oxygen using an animal
ventilator  (Surgivet),  a  1  cm  incision  was
made on the back between the scapulae, and
micro-osmotic pumps containing isoproterenol
dissolved  in  a  saline  solution  (0.9%  NaCl)




Increased  pressure  in  the  proximal  aorta
was  induced  by  means  of  transverse  aortic
banding (TAB), as previously described.
18 Male
mice  (C57Bl6,  eight  weeks  old)  were  anes-
thetized with ketamine (100 mg/kg IP) plus
xylazine (5 mg/kg IP), orally intubated with
20-gauge  tubing,  and  ventilated  (Harvard
Apparatus  Rodent  Ventilator,  model  687)  at
120 breaths per minute (0.1-mL tidal volume).
A 3-mm left-sided thoracotomy was performed
at  the  second  intercostal  space.  The  trans-
verse  aortic  arch  was  ligated  (7-0  Prolene)
between  the  innominate  and  left  common
carotid  arteries  with  an  overlying  27-gauge
needle,  and  then  the  needle  was  removed,
leaving  a  discrete  region  of  stenosis.  The
chest  was  closed,  and  the  left-sided  pneu-
mothorax  was  evacuated.  Perioperative  (24
hours)  and  one-week  mortalities  were  less
than 10% each. Mice were sacrificed after 21
days of experimentation.
Heart rates
Non-invasive recording of heart rate (HR)
and  electrocardiogram  (ECG)  were  accom-
plished  in  conscious  mice  using  the
AnonyMouse™ ECG Screening System (Mouse
Specifics, Inc., Boston, MA, USA).
19 Mice were
rested (i.e. not manipulated) for at least 10 min
before  readings  were  recorded.  For  each
mouse, a reading was obtained by averaging
the first three readings of more than 5 sec.
Administration of doxycycline 
and carbamazepine
Doxycycline (Sigma Aldrich) was given at 6
mg/mL  in  drinking  water  containing  5%
sucrose.  Control  animals  were  given  5%
sucrose  water.  Carbamazepine  was  adminis-
tered in rodent chow by mixing powdered chow
with 0.25% carbamazepine. Water was added
to  the  dry  chow  mix  at  the  ratio  0.8:1
water:powder  by  weight  and  the  resulting
paste diced and dried overnight at 60°C. The
half-life for doxycycline is shortened when co-
administered with carbamazepine.
20 Therefore
we increased the concentration of doxycycline
to 10 mg/mL in 7% sucrose water in co-admin-
istration experiments. Control animals in co-
administration  experiments  received  7%
sucrose in water.
Microarray sample preparation and
analysis
Mice were sacrificed by cervical dislocation
after the animals were anesthetized with 3:97
isoflurane  and  oxygen  mix.  Animals’  hearts
were  then  rapidly  removed  and  the  blood
flushed out with 3 mL of 0.9% saline solution.
The atria and right ventricles were cut from
the heart and immediately plunged into TRIzol
Reagent (Life Technologies). Total RNA was
isolated following the manufacturer’s instruc-
tions, purified by phenol-chloroform extraction
and ethanol precipitation, and 20 μg further
processed  for  microarray  analysis.  Briefly,
cDNA  synthesis,  in  vitro transcription,  and
labeling  and  fragmentation  to  produce  the
oligonucleotide  probes  were  performed  as
instructed  by  the  microarray  manufacturer.
The probes were first hybridized to a test array
(Affymetrix) and then to the GeneChip Mouse
Genome 430 2.0 Array (Affymetrix), using the
GeneChip  Hybridization  Oven  640
(Affymetrix).  The  chips  were  washed  in  a
GeneChip  Fluidics  Station  450  (Affymetrix),
and  the  results  were  visualized  with  a
GeneChip  G7  scanner  (Affymetrix).  One
mouse heart was used for each array, and the
experiment  was  performed  in  triplicate  for
four conditions (ISO, ISO + DOX, ISO + CBZ,
ISO + DOX + CBZ) generating a total of 12
arrays.    GeneSifter  (VizX  Labs,  Seattle,  WA,
USA) was used to perform RMA normalization,
pairwise  comparisons  of  averaged  signal
intensity  values,  and  Student’s  t-test  with
Benjamini  and  Hochberg  correction,  and
Spotfire  DecisionSite  8.3  (Spotfire,  Inc.,
Somerville, MA) was used to perform pairwise
comparisons of the individual experiments. A
gene was considered significantly altered in
expression  if  the  average  fold-change  value
was at least 2.0, the fold change for each indi-
vidual replicate comparison was at least 1.5,
and the corrected P value was less than 0.05.
Additionally, genes that were altered between
any two normal or any two ISO-treated samples
were removed, as these alterations most likely
represented normal variations between mice. 
Real-Time reverse transcriptase-
polymerase chain reaction
Quantitative RT-PCR was performed in the
iCycler iQ multi-Color real-time PCR detection
system  (Bio-Rad,  Hercules,  CA,  USA)  using
SYBR Green I dye (Qiagen, Valencia, CA, USA)
as described by the manufacturer. Briefly, 100
ng of RNA was placed into a 25 μL reaction vol-
ume  containing  2.5  μL  of  each  primer  set
(Quantitect Primer Assays, Qiagen), 12.5 μL
SYBER Green PCR master mix, and 0.25 μL
reverse transcriptase. A typical protocol includ-
ed reverse transcription at 50°C for 30 min and
a denaturation step at 95°C for 15 min followed
by 35 cycles with 94°C denaturation for 15 sec,
55°C annealing for 30 sec, and 72°C extension
for 30 sec. Detection of the fluorescent product
was  performed  at  the  end  of  the  extension
period at 60°C for 20 sec. The PCR products
were subjected to a melting curve analysis to
confirm  amplification  specificity.  Negative
controls containing water instead of RNA were
run concurrently to confirm that the samples
were  not  cross-contaminated.  Targets  were
normalized  to  reactions  performed  using
Quantitect GAPDH primer assay (Qiagen), and
fold change was determined using the compar-
ative threshold method.
21Article
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Histology
Animal hearts were excised and fixed with
10% phosphate-buffered formalin for 48h, and
then  embedded  in  paraffin.  Cross-sectional
slices in the minor axis were obtained with a
microtome  and  the  slices  stained  using
Mayer's hematoxylin and eosin (H&E).
Immunoblotting 
Left ventricles were homogenized in 100 mM
Tris-HCl (pH 7.4) containing 15% glycerol, 2 mM
EDTA, 2% SDS, and 0.1 mM phenylmethylsul-
fonylfluoride. Homogenates were heated at 95°C
for 10 min, passed through a 23-gauge needle
five  times,  and  centrifuged  at  12,000g  for  10
min.
22Proteins (80 μg/mL) were resolved by 10%
SDS-PAGE  and  electrophoretically  transferred
onto  a  nitrocellulose  membrane  (Amersham
Hybond, GE Healthcare, NJ, USA). Membranes
were blocked with 5% milk (Bio-Rad, CA, USA)
and probed with affinity-purified antibodies at
1:1000 dilution. Membranes were subsequently
incubated  with  horseradish  peroxidase-conju-
gated  secondary  antibody  (Cell  Signaling
Technology,  MA,  USA)  and  then  exposed  to
chemiluminescence substrate (GE Healthcare).
Affinity-purified  anti-CREB-P  and  anti-GAPDH
antibodies  were  purchased  from  Santa  Cruz
Biotechnology Inc. (Santa Cruz, CA, USA). Band
intensities and sizes were obtained using Adobe
Photoshop CS3 (Adobe Systems Inc, CA, USA).
Statistical analysis
Values  presented  are  expressed  as  mean  ±
S.E.M. All comparisons between groups were per-
formed using a one-way ANOVA followed by the
Newman-Keuls test. Differences were considered
to be statistically significant when P<0.05.
Results
Carbamazepine is beneficial    
in cardiac hypertrophy
In the isoproterenol induced cardiac hyper-
trophy  model,  the  untreated  mouse  exhibits
severe hypertrophy while the carbamazepine
treated heart has a structure that is relatively
well preserved, suggesting that carbamazepine
treatment  reduced  ISO-induced  hypertrophy
(Figure  1).  Carbamazepine  significantly
decreased  the  heart  weight  to  tibia  length
(HW/TL) ratio (7.14 mg/mm vs. 9.92 mg/mm,
P<0.0001,  n=10  mice  per  group)  and  heart
weight  to  body  weight  (HW/BW)  ratio  (5.7
mg/g vs. 6.8 mg/g, P<0.01, n=5 mice per group;
Figure 1). In the TAB model, carbamazepine
also seems to attenuate cardiac hypertrophy as
the HW/BW were 6.02 mg/g versus 5.61 mg/g
for the TAB group and the TAB+CBZ group,
respectively (n= 5 mice per group). However
the P value is slightly above the significance
threshold  (P=0.07)  suggesting  that  carba-
mazepine likely has an effect but not as visible
in  the  case  of  the  TAB  model.  The  HW/BW
ratios show that co-administration of doxycy-
cline  and  carbamazepine  together  reduces
hypertrophy more than either drug adminis-
tered alone. This partially additive effect of the
two  drugs  strongly  supports  the  hypothesis
that the two drugs act via different CH-associ-
ated pathways and that targeting both path-
ways simultaneously resulted in better thera-
peutic  performance  in  the  mouse  model.
Figure 2 shows that this benefit resulted in a
Figure 1. (Top panel) The combination of DOX+CBZ provides added therapeutic benefit
relative to either drug alone in mice with ISO-induced cardiac hypertrophy. P values are
obtained from a one-way ANOVA. The experiment lasted 10 days. DOX was given at 10
mg/mL in 7% sucrose water. CBZ was given in chow at 0.25%. The control group (ISO
only) received regular chow and 7% sucrose water. Each circle is the heart to body weight
ratio  for  one  mouse  and  the  dashes  are  the  average  for  each  group.  (Bottom  panel)
Histological cross sections of mouse hearts of CBZ-treated and untreated mice. (A) Wild
type control mouse (C57BL/6J). Heart weight (HW) = 0.1305 g; body weight (BW) =
26.3g. (B) ISO-treated CBZ-untreated mouse. HW=0.1800g; BW=26.3g. (C) ISO- and
CBZ-treated mouse. HW=0.1415, BW=26.3. 
Figure 2. The com-
bination of DOX +
CBZ reduces hyper-
trophy and increas-
es  survival  relative
to  ISO  treatment
alone. There were 6
mice in each group.
One mouse was sac-
rificed on day 7 in
each group. Article
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substantial increase in survival time.
We  also  measured  the  heart  rates  of  the
mice before induction of cardiac hypertrophy
and after nine days of treatment. As expected,
the β-adrenergic agonist isoproterenol caused
an observable increase in heart rate for each
mouse compared to measurements taken prior
to  isoproterenol  treatment  (Figure  3).  The
maximum heart rate was 821 beats per minute
for the isoproterenol group versus 780 for the
cardiac hypertrophy group treated with CBZ +
DOX  (P<0.01,  n=5).  A  one-way  ANOVA  fol-
lowed  by  a  Newman-Keuls  test  P  value  for
heart rate variations is 0.007 and indicates sta-
tistically  significant  differences  between
groups  of  mice  classified  as  follows:
ISO=DOX>CBZ=(CBZ+DOX)  (P<0.01,  n=5),
which  indicates  that  attenuation  of  the
increased heart rate induced by isoproterenol
is mediated by carbamazepine. Further, since
no change in heart rate was observed between
ISO- and ISO + DOX-treated mice, the mecha-
nism of action of doxycycline is likely inde-
pendent of the β-adrenergic pathway. 
Effects on gene expression profile
To assess the effect of doxycycline and car-
bamazepine  on  cardiac  gene  expression,
microarray analyses were performed on nor-
mal (no drug) mice (N) and mice with ISO-
induced cardiac hypertrophy that were subse-
quently untreated (CH) or treated with DOX,
CBZ, or DOX + CBZ. Based on various selec-
tion  criteria  (see  Materials  and  Methods),
there were 779 genes that were significantly
altered between N and CH mice. Of these 779
genes, 327 and 472 were altered in the reverse
direction when mice were given doxycycline or
the combination drug treatment, respectively.
Only one gene was significantly altered, based
on the stringent analysis criteria used, in mice
treated with carbamazepine alone. This gene
(G7e protein) encodes a viral capsid protein of
otherwise unknown function (-2.2-fold).
Of the 472 “CH-specific” genes that were
altered in response to treatment with DOX +
CBZ, 453 and 98 were also altered when either
doxycycline or carbamazepine alone was used,
when statistical parameters were lifted (i.e.,
average fold changes irrespective of statistical
measures). The remaining 19 genes were only
altered in mice given isoproterenol, compared
to normal mice, and in mice given the doxycy-
cline + carbamazepine drug therapy (in the
opposite direction), but not when either drug
was administered alone. Presumably these 19
genes represented transcriptional alterations
observed that correlate with the additive effect
of both drugs. Functions of these genes includ-
ed  those  involved  in  transport  processes,
cytoskeleton  movement/adhesion,  and  mus-
cle/heart development. Eighteen of the gene
alterations that were determined to be differ-
entially expressed between disease conditions
were verified by real-time RT-PCR (Table 1). 
Effects on CREB phosphorylation
Carbamazepine attenuates the ISO-induced
phosphorylation of CREB (Figure 4) confirm-
ing the anti-adenylate cyclase activity of carba-
mazepine.
14This attenuation is likely responsi-
Table 1. Real-time RT-PCR results for selected genes.
Microarray  Real-time RT-PCR
Gene name Function FC
CH ComboDOX CBZ CH Combo DOX CBZ
DNA-damage-inducible transcript 4 (Ddit4) Hypoxic stress response; cell growth 7.4 -6.2 -5.6 - 13.9 -2.5 -5.7 -
Matrix metalloproteinase 3 (Mmp3) Extracellular matrix remodeling 7.4 -3.6 -2.9 - 5.3 -1.5 -3.5 -2.5
Metallothionein 1 (MT2) NO-mediated signal transduction 15.6 -6.8 -5.5 - 19.7 -2.8 -14.9 -
Tubulin, alpha 4 (Tuba4) Microtubule-based movement -6.2 5.8 5.8 - -26.0 27.9 36.8 -
GATA binding protein 4 (Gata4) Transcription regulation; heart development -3.0 4.0 2.7 2.1 -3.3 8.6 4.9 2.0
Serine protease inhibitor 2-2  Acute-phase response; inflammation 40.5 -12.7 -9.7 -2.3 90.5 -18.4 -3.8 -13.9
(Spi2-2) (Serpin3n)
Transformation related protein 53 inducible  Stress response; apoptosis 4.8 -5.0 -3.5 - 6.1 Red -1.9 -3.0
nuclear protein 1 (Trp53inp1)
NADPH oxidase 4 (Nox4) Electron transport; superoxide release 4.3 -3.4 -3.2 -1.9 22.6 -2.5 -4.0 -3.5
Gem GTPase (Gem) Calcium channel blockage 2.7 -2.9 -2.8 - 8.0 -1.7 -1.8 -
Oncostatin receptor (Osmr) Inflammation; connective tissue production;  5.1 -2.9 -2.6 -1.7 Ind Red Red Red
extracellular matrix turnover
Phospholipase A2 group VII (platelet-activating Inflammation; lipid catabolism 3.7 -2.3 -2.2 - 7.5 -2.0 -1.9 -3.5 
factor acetylhydrolase, plasma) (Pla2g7)
SET and MYND domain containing 1 (Smyd1) Heart development -2.9 3.2 2.7 1.7 -1.7 4.9 1.6 3.3
Lipocalin 2 (Lcn2) Vascular remodeling; apoptosis 27.7 -16.6 -13.3 -1.6 64.0 -7.0 -9.9 -
Cyclin-dependent kinase inhibitor 1A  Cell cycle arrest 14.6 -8.6 -6.5 - 128.0 -13.0 -7.0 -2.5
(p21) (Cdkn1a)
S100 calcium binding protein A8  Cell proliferation; calcium signaling 7.1 -14.3 -19.9 - 5.7 -137.2 -181.0 -2.1
(calgranulin A) (S100a8)
S100 calcium binding protein A9  Cell proliferation; calcium signaling 7.1 -15.9 -14.0 - 17.2 -52.0 -104.0 -
(calgranulin B) (S100a9)
Cyclin G2 (Ccng2) Cell cycle regulation 3.4 -3.8 -3.1 - 9.2 -2.6 -5.7 -
Cytokine inducible SH2-containing  Regulation of cell growth;  8.2 -7.9 -4.9 -2.4 9.9 -4.0 -4.0 -4.3
protein 3 (Socs3) negative regulation of insulin signaling
N: normal mice; CH: ISO-treated mice; DOX: mice treated with ISO + DOX; CBZ: mice treated with ISO + CBZ, and Combo: mice treated with ISO + DOX + CBZ.
FC: fold change. Ind/Red (Induced/reduced) are used instead of fold changes where no transcript was detected in one of the two samples being compared.   Article
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ble for the anti-chronotropic effect of carba-
mazepine  in  mice  receiving  isoproterenol
(Figure 3). Although doxycycline administra-
tion results in a limited attenuation of CREB
phosphorylation,  it  may  likely  be  a  conse-
quence of doxycycline anti-hypertrophic activi-
ty.  Furthermore  and  unlike  carbamazepine,
doxycycline had no significant action on the
isoproterenol  induced  chronotropic  effect
(Figure 3). 
Discussion 
The results of this study suggest that carba-
mazepine  attenuates  ISO-induced  cardiac
hypertrophy, an effect that is even more pro-
nounced when it is administered concurrently
with  doxycycline.  Further,  the  beneficial
effects of the DOX + CBZ combination therapy
included  an  increased  survival  rate  and
decreased heart rate, the latter of which was
also  observed  when  carbamazepine  was
administered alone. Because one of the major
actions of isoproterenol is an increase in heart
rate,  presumably  via  stimulation  of  the  β-
adrenergic pathway, this study suggests that
carbamazepine  interferes  with  β-adrenergic
signaling.  The  β-adrenergic  stimulation  is
mediated via a G protein, coupled to adenylate
cyclase. Because carbamazepine has been pre-
viously shown to inhibit adenylate cyclase,
14 it
is reasonable to assume that this has indeed
occurred in our system as well, especially given
the  decreased  hypertrophy  and  lower  heart
rate  observed  in  carbamazepine-treated  ani-
mals  compared  to  mice  treated  with  isopro-
terenol alone.   
Additionally,  carbamazepine  was  found  to
have a more visible action in the ISO-induced
model in comparison with the TAB model. This
is  likely  due  to  the  different  mechanisms
involved  in  the  induction  of  hypertrophy  in
these models. The isoproterenol model is pri-
marily mediated via β-adrenergic stimulation
on  the  heart,  while  the  TAB  model  likely
involves  many  different  pathways.  Assuming
that  carbamazepine  acts  as  a  β-adrenergic
antagonist (via the AC inhibition), it is not
surprising  that  the  carbamazepine  effect  is
more visible in the ISO-induced model.
The likely mechanism of action of doxycy-
cline in the context of cardiac hypertrophy is
the  inhibition  of  matrix  metalloproteinases
(MMPs), which are known to contribute to the
hypertrophic phenotype.
13 There is no reason
to believe that doxycycline might exert a nega-
tive effect on β-adrenergic signaling, especial-
ly since no decrease in heart rate was observed
in response to doxycycline treatment. This is
consistent with previous work, in which non-
selective inhibition of MMPs and knock out of
specific MMP genes failed to alter blood pres-
sure or heart rate in mice.
23-25 Carbamazepine,
in  contrast,  has  been  correlated  with  lower
blood  pressure  and  heart  rates  in  epileptic
patients
26-28 and  has  no  toxic  cardiovascular
effects.
29 The observation that carbamazepine
counters  the  positive  chronotropic  effect
induced by isoproterenol via depression of β-
adrenergic signaling is in accordance with pre-
vious  work
14 and  our  hypothesis  that  carba-
mazepine  inhibits  adenylate  cyclase  in  car-
diomyocytes in vivo. 
While carbamazepine was clearly beneficial
to mice after induction of cardiac hypertrophy,
there was very little transcriptional alteration
in  carbamazepine-treated  animals  compared
to those treated with doxycycline alone or with
the drug combination. It is possible that the
mechanism of action for carbamazepine lies in
its  ability  to  activate  and/or  inhibit  cardiac
hypertrophy-specific  proteins  post-transcrip-
tionally and perhaps act additively with doxycy-
cline  by  targeting  those  proteins  that  are
increased at the level of transcription by doxy-
cycline  treatment.  Regardless  of  how  this
might be accomplished, however, several car-
diac-related genes were altered by these two
drugs when administered alone and/or in com-
bination. For instance, the gene that encodes
cAMP-specific phosphodiesterase 4A (PDE4A),
which  inactivates  cAMP,  was  decreased  in
response  to  isoproterenol  treatment  and
restored in response to drug therapy. It was
also possible to correlate 19 genes with the
added benefits observed during the combina-
tion therapy (DOX + CBZ). These genes may
serve as research tools to uncover the underly-
ing molecular mechanisms leading to cardiac
hypertrophy.  Interestingly,  one  of  these  19
genes is the α-adrenergic receptor (Adra1b),
which has been recently demonstrated to pre-
Figure 3. HR variation over the
course of the experiment (aver-
age+SEM)  of  mice  receiving
ISO, or ISO+DOX, ISO+CBZ,
or  ISO+DOX+CBZ.  HRs  were
measured at the beginning of the
experiment and one day before
the  sacrifice.  Each  HR  is  the
average of 3 measurements. The
experiment lasted ten days. The
one-way  ANOVA  P  value  is
0.007 and indicates differences
in  groups  (n=5).  A  Newman-
Keuls test led to the conclusion
that groups can be classified as
follows:  ISO=DOX>CBZ=
(CBZ+DOX.  *Indicates  signifi-
cant differences.
Figure 4. Both CBZ and
CBZ+DOX  attenuate
the  ISO-induced  phos-
phorylation  of  CREB.
(Top  panel)  Western
immunoblot from heart
protein extracts showing
levels  of  P-CREB.
(Bottom  panel)  Band
intensity and size quan-
tification. Article
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vent  a  maladaptive  cardiac  response.  This
gene  was  down-regulated  in  isoproterenol
mice and completely restored to basal levels
after treatment with the DOX + CBZ combina-
tion (2.3-fold).   
Additionally, carbamazepine has also been
shown  to  inhibit  histone  deacetylase
(HDAC),
30 transcriptional modulators of genes
involved  in  the  hypertrophic  response.
Increasing evidence demonstrates that inhibi-
tion of HDACs, particularly of class II (prefer-
entially expressed in the heart
31) but also class
I might be an efficient therapeutic strategy.
32-34
Therefore, we cannot exclude the HDAC inhi-
bition potential of carbamazepine as a rational
explanation of its beneficial effect nor can we
exclude the involvement of both pathways in
the therapeutic effect of carbamazepine. 
Since  carbamazepine  and  doxycycline  are
both already FDA approved for use as an anti-
epileptic (CBZ) and antibiotic (DOX), the two
drugs may be attractive candidates for thera-
pies that complement currently accepted med-
ications used to treat and prevent the disas-
trous effects of prolonged long-term hyperten-
sion. In epileptic patients, carbamazepine may
cause  problematic  side  effects  such  as  fluid
retention  and  aggravation  of  hyponatremia
when combined with thiazides. As such, cau-
tion should be used when considering off-label
prescription of carbamazepine and doxycycline
to prevent any adverse effect. Additional exper-
iments  to  assess  the  safety  and  efficacy  of
these drugs for cardiac hypertrophy are war-
ranted. 
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